08:00 , Jan 23, 2006 |  BioCentury  |  Finance

Back on Targacept

When Targacept postponed and later pulled its IPO last year, the company had both external and internal factors working against it. Externally, the company was on the road in the first quarter - the dismal...
07:00 , Apr 26, 2004 |  BC Week In Review  |  Clinical News

Ranexa: Phase III data

Previously reported result from the Phase III MARISA trial in 191 angina patients showed Ranexa increased symptom-limited exercise duration (p<0.005). Ranexa also increased the secondary endpoint of time to onset of angina pain during exercise...
07:00 , Jul 14, 2003 |  BC Week In Review  |  Company News

CV Therapeutics, Quintiles sales and marketing update

The companies amended a 1999 deal for QTRN's Innovex subsidiary (Parsippany, N.J.) to provide a sales force and fund marketing activities in the U.S. for CVTX's Ranexa ranolazine, which is under FDA review to...
08:00 , Jan 2, 2001 |  BC Week In Review  |  Clinical News

Ranolazine: Began Phase II trial

CV Therapeutics Inc. (CVTX), Palo Alto, Calif.   Product: Ranolazine   Business: Cardiovascular   Therapeutic category: Metabolism   Target: Enoyl-CoA-hydratase   Description: Anti-ischemic agent; partial fatty acid oxidation (pFOX) inhibitor   Indication: Treat congestive heart failure (CHF)   End point:...